Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Q2 marked continued progress for Medivir in advanced liver cancer

At the ESMO GI congress in June, Medivir presented greatly improved results for patients with advanced liver cancer in the ongoing phase Ib/IIa study with fostrox in combination with Lenvima. The company is increasingly optimistic about the possibility of launching the first approved drug treatment after first-line treatment of the disease. This is evident from Medivir’s interim report.– We are now looking forward to presenting detailed and mature clinical data from the study with fostrox at the ESMO Cancer Congress in Barcelona in September, says CEO Jens Lindberg.Read the full article

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 184 – 26 AUGUST 2024   On 9 August 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 9 August 2024 up to and including no later than 23 October 2024. For details, please see announcement no. 171 of 8 August 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 14 million (approximately DKK 95 million).

BioStock: Lipum recruits new CMO – “I have been following their research for a while and am impressed”

In preparation for the continued clinical development of SOL-116 in rheumatoid arthritis, Lipum has strengthened its management team by appointing Peter Hovstadius as the new Chief Medical Officer. Peter brings extensive experience in clinical drug development from leading roles at companies such as XNK Therapeutics, Novartis, and MSD.– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter in an interview.Read the full article at biostock.se 

DecideAct strengthens its growth opportunities in the US and Canada by achieving SOC2 type II security certification

The SOC 2 type II certification supports DecideAct's growth ambitions in the US and Canadian markets by providing comprehensive benefits that improve trust, compliance, security, operational efficiency, and competitive positioning. Thus, it is a strategic investment that can facilitate market entry, customer acquisition, and long-term growth.Many organizations in the US and Canada, especially those in regulated industries like finance, healthcare, and technology, require their service providers to have SOC 2 certification. For a SaaS company like DecideAct with growth ambitions in the US

Careium launches SaaS alarm management and IoT platform i-Care Center, securing MD Medicus as the first external customer

Careium, a European champion in technology enabled care, announces the launch of i-Care Center, a unique end-to-end SaaS platform for management of alarms, sensors and IoT solutions for seniors, enabling rich, safe, and active lives via the Careium ecosystem. The first customer, MD Medicus, is a leading player within medical and care services, based in Germany with a genuinely global footprint. MD Medicus serves more than 60,000 connected seniors with its care services, and in addition provides care and healthcare support via its insurance partners to 20 million people worldwide. The

BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease

Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva's development moving forward.Watch the interview with Abliva ’s CEO Ellen Donnelly at biostock.se: Abliva's CEO: We are the leading programme in mitochondrial disease - BioStock  This is a

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 26 August 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 1,000,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to purchase one share in the Company. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during

Repurchase of Truecaller B shares in week 34, 2024

During 19 August 2024 and 23 August 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 180,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 28 May 2024. The share buyback programme will run between 28 May up until the 2025 AGM which will be held in May 2025, and is carried out in accordance “Emittentregelverket”. On the Annual General Meeting 2024 the Board was authorized to buy back B-shares up until the

Dicot informs about last day for subscription of units in ongoing rights issue

Uppsala, Sweden, August 26, 2024. Friday August 30, 2024, is the last day for subscription in Dicot Pharma's ongoing rights issue of units of approximately SEK 122.6 million (the "Rights Issue"). Please note that some banks and nominees have an earlier date for subscription deadlines. Holders of unit rights should therefore check with their bank or nominee whether they use an earlier closing date for subscription. The last day of trading in unit rights on Spotlight Stock Market is August 27, 2024.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED

Consulting firms continue to face challenges in the second quarter

Despite favorable calendar effects, growth remains low for consulting firms in the Nordics for the second quarter. The average growth was 3.1 percent, compared to 7.5 percent last year. However, this was a step in the right direction considering the negative growth in the first quarter. The number of layoffs in the industry continues, and 70 percent of companies have reduced their number of employees. This is shown in Cinode’s latest summary of the Q2 reports from publicly listed consulting firms. 

Shape Robotics receives its first order of 50 Thinken units from Lenovo under its newly announced pan-European partnership with Channel Tools

Herlev, Denmark – 26 August 2024 – Shape Robotics A/S, a leader in educational robotics, has received its first order of 50 units of its flagship product, the Thinken Mobile STEAM Lab, as part of a newly announced pan-European partnership with Channel Tools (see press release dated 22 April 2024). The order, placed by Lenovo, is part of a larger, undisclosed pool of potential orders that may be fulfilled over the next 3 to 4 quarters. Lenovo’s order comes just one week after Shape Robotics was officially listed as part of Lenovo’s Third-Party Options (3PO) program, designed to expand

Crunchfish half-year report 2024 webinar

Crunchfish AB (“Crunchfish”) half-year report 2024 webinar is now available, where Crunchfish CEO Joachim Samuelsson is interviewed by Chief Analyst Martin Dominique from Västra Hamnen Corporate Finance.[Two men sitting at a table Description automatically generated]   The webinar about Crunchfish half-year report for 2024 is now available via the following link: Webinar half-year report    Crunchfish half-year report for 2024 is available via the following link: Crunchfish half-year report 2024 

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.   · Proveca has been granted a non-exclusive option to license Cessatech’s CT002 program. · Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England.On 26 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company

Neola’s CEO to BioStock: “We are now preparing for a clinical study in the US”

After recently receiving a CB certificate for its medical device, intensive work is now underway at Neola Medical to prepare for the clinic. As part of this, a clinical pilot study will be carried out together with a neonatal ward in Sweden. – This is a step to optimize the conditions for a successful clinical study in premature babies in the United States, CEO Hanna Sjöström tells BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/08/neolas-ceo-we-are-now-preparing-for-a-clinical-study-in-the-us/ This is a press release

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act

Neste Corporation, Stock Exchange Release, 26 August 2024 at 9:15 a.m. (EET)Neste Corporation has on 23 August 2024 received a notification under Chapter 9, Section 10 of the Finnish Securities Market Act (FSMA). According to the notification by BlackRock, Inc., the aggregate holdings of the entities referred to therein excluding financial instruments according to SMA 9:6a have on 22 August 2024 decreased to below 5% of the total number of shares and voting rights of Neste Corporation. The aggregate holdings including financial instruments according to SMA 9:6a owned by BlackRock, Inc.

Strong improvement of balance sheet by early repayment of debt, positive operating cash flow and continuous positive development in EBITDA in 2024-H1

Company Announcement No. 11 - 20242024-H1 financial report Management commentaryIn 2024-H1, Donkey Republic realized revenues of DKK 59.8M and improved EBITDA by 75% compared to 2023-H1.These results showcase successful strategy execution, with positive operating cash flow underscoring our focus on efficiency and profitability. This positive cash flow allowed for early debt repayment, significantly strengthening our balance sheet. Additionally, in 2024-Q2 we rolled out our operation in Hannover, Germany and commenced the long term B2G contract which was awarded in 2023-Q4. We look

ContextVision publishes Webcast for Q2 2024

Watch CEO Gerald Pötzsch and CFO Richard Hallström present ContextVision’s highlights from Q2 2024 along the financials for the quarter. The Webcast is available on ContextVision’s website following the link below: https://www.contextvision.com/investors/webcast/ For more details, contact ContextVision’s CFO, Richard Hallström at richard.hallstrom@contextvision.com or visit our official website at www.contextvision.com. About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market

ContextVision AB: Q2 interim report 2024 - Strong cash position supports continued investment in Image and Data Quality

Q2 Highlights · New customers signed in Asia and North America. ContextVision now has potential to expand its footprint in North America in different segments. · Stable cash flow and good cash position enable continued investments in image quality and in data quality. · Progress in Point-of-Care Ultrasound (POCUS) as ContextVision enters early stages of the development of new product pipeline for organ specific applications. · Final stage of signing an advanced development partnership regarding POCUS. Q2 Financial Data · Net Sales of 31.7 MSEK (33.8), down -6.2%. ·

CYBER1 - Great potential in cybersecurity - Mangold Insight Analysis

Mangold updates Cyber Security 1 (“CYBER1”). Revenues increased to EUR 28.7 (25.1) million in the first half of 2024, corresponding to a growth rate of around 15 percent. The revenue was in line with our estimate, which we believe shows that the company is on the right path. The gross margin was 21.0 (22.5) percent, which was slightly lower than estimate. However, personnel costs and other costs were lower than we expected, which means that we will lower the operational costs moving forward. We continue to estimate that CYBER1 will achieve full-year profitability in 2024. Mangold welcomes

Veidekke: Exercise of employee share options in Veidekke ASA

A total of 20 participants in the Company's share option program have on August 23[rd] 2024 exercised a total of 18 775 options at a strike price of NOK 39.46.A total of 50 participants in the Company's share option program have on August 23[rd] 2024 exercised a total of 45 463 options at a strike price of NOK 99.36. Shares acquired through the program have a sales restriction on one year after exercise date.Following the exercise, the employees will purchase 64 238 shares. These shares will be transferred during September.  5 500 options have been exercised by primary insiders.

FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS   Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   Key highlights -          Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron’s BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS -          FTD further strengthens the bexmarilimab program by offering clinical development and commercialization

There are no items matching the current filter
There are no more items matching the current filter
Back to top